Our studies suggest a novel mechanism by which the PARP-1 inhibitor, Olaparib, effectively enhances GLP-1 activity in the setting of hyperglycemia and could represent an alternative therapeutic avenue to that of DPP-IV inhibition for T2D. Here, DPP4 is linked to type 2 diabetes mellitus.